Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | BCR | P11274 | 3/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14800904 | 0.87 | CTSC (0.54) | CTSCCHRNA7KCNH2SCN5ASCN9A | |
| SCHEMBL20267818 | 0.81 | CTSC (0.54) | CTSCCHRNA7KCNH2SCN5ASCN9A | |
| SCHEMBL14411849 | 0.81 | KCNH3 (0.43) | KCNH2SCN9ADHODHTDO2 | |
| SCHEMBL24866863 | 0.78 | TDO2 (0.53) | CTSCCHRNA7KCNH2SCN5ASCN9A | |
| SCHEMBL9062115 | 0.76 | RXRA (0.48) | CHRNA7KCNH2SCN5ASCN9ARXRA | |
| SCHEMBL20267833 | 0.76 | CTSC (0.45) | CTSCCHRNA7KCNH2SCN5ASCN9A | |
| SCHEMBL28396861 | 0.75 | NPC1 (0.51) | CTSCKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL3647348 | 0.75 | CDK4 (0.50) | CHRNA7 | |
| SCHEMBL21755169 | 0.75 | HDAC6 (0.49) | TP53MAPT | |
| SCHEMBL9062321 | 0.75 | RXRA (0.47) | CHRNA7KCNH2SCN5ASCN9ARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996198-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | Kalypsys, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109577-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | CTSC 1014/4885CHRNA7 1534/4885KCNH2 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.